Jasper Therapeutics (NASDAQ:JSPR) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of Jasper Therapeutics (NASDAQ:JSPR) from a sell rating to a hold rating in a report issued on Saturday morning.

A number of other analysts have also issued reports on the stock. HC Wainwright reiterated a “buy” rating on shares of Jasper Therapeutics in a research note on Tuesday, August 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Friday, July 17th. Piper Sandler assumed coverage on shares of Jasper Therapeutics in a report on Wednesday, August 12th. They issued an “overweight” rating and a $2.00 price objective for the company. TD Cowen downgraded shares of Jasper Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 15th. Finally, Royal Bank Of Canada set a $3.00 target price on shares of Jasper Therapeutics and gave the stock a “sector perform” rating in a report on Friday, May 15th. Six research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $8.17.

Jasper Therapeutics Trading Up 0.1%

Shares of NASDAQ JSPR opened at $0.70 on Friday. The stock has a market capitalization of $23.29 million, a PE ratio of -0.44 and a beta of 3.02. Jasper Therapeutics has a twelve month low of $0.32 and a twelve month high of $2.87. The stock has a fifty day simple moving average of $0.65 and a 200-day simple moving average of $0.86.

Jasper Therapeutics (NASDAQ:JSPR) last posted its earnings results on Friday, August 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.17. On average, equities analysts predict that Jasper Therapeutics will post -1.32 earnings per share for the current year.

Institutional Investors Weigh In On Jasper Therapeutics

Several large investors have recently bought and sold shares of JSPR. ADAR1 Capital Management LLC purchased a new position in shares of Jasper Therapeutics in the 4th quarter valued at about $256,000. Quarry LP purchased a new stake in shares of Jasper Therapeutics during the fourth quarter worth approximately $182,000. Knott David M Jr increased its stake in shares of Jasper Therapeutics by 5.8% during the fourth quarter. Knott David M Jr now owns 181,389 shares of the company’s stock worth $332,000 after buying an additional 10,000 shares during the period. Two Sigma Investments LP purchased a new stake in shares of Jasper Therapeutics during the third quarter worth approximately $96,000. Finally, Marshall Wace LLP acquired a new stake in Jasper Therapeutics in the second quarter valued at approximately $281,000. Hedge funds and other institutional investors own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.